Caplight Directory>Companies>Infex Therapeutics-preview>Infextx


Infex Therapeutics

Infex Therapeutics

Private
Alderley EdgeN/Ahttps://www.infextx.com/

Last Round

Early Funding

May 12, 2026

Total Funding Raised

$5M

Momentum Score

25 /100

Company Overview

Infex Therapeutics is a biotechnology company that acquires, develops, and licenses innovative drugs to treat pandemic and critical priority infectious diseases.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Infex Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Infex Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 12, 2026
View all Funding Rounds

Key People

Founding team and executive leadership

Dawn Watson

CFO

Executive Team

Infex Therapeutics Investors

Notable investors and investment history

InvestorRounds
Greater Manchester and Cheshire Life Science FundEarly Funding
Catapult VenturesEarly Funding
Catapult VenturesEarly Funding
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    $5.8M round led by Jon Moulton

  • Mar 2, 2026

    Monthly visitors grew 47% MoM, from 961 to 1.4K.

View all signals

Infex Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Infex Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Infex Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAlderley Edge
Employee Range24
Year Founded2016
Last FundingMay 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.